In an adult with treatment‑resistant depression and anhedonia, can lithium be used as augmentation therapy, and what are the recommended starting dose, titration schedule, target serum level, and monitoring parameters?

Lithium for Anhedonia in Treatment-Resistant Depression

Yes, lithium can be used as augmentation therapy for treatment-resistant depression with anhedonia, starting at 150-300 mg daily, targeting serum levels of 0.2-0.6 mEq/L (lower than traditional bipolar dosing), with monitoring of serum levels, renal function, and thyroid function.

Evidence Base for Lithium Augmentation

Lithium augmentation is a first-line, evidence-based strategy for treatment-resistant depression 1, 2, 3. The evidence is robust: a meta-analysis of 10 randomized controlled trials demonstrated significant efficacy versus placebo (odds ratio 3.11, NNT=5, response rate 41.2% vs 14.4% placebo) 3. This represents one of the best-documented approaches in refractory depression 4, 2.

While the evidence specifically for anhedonia is limited, a 2026 meta-analysis found that treatments for depression (including augmentation strategies) showed only small effects on anhedonia (SMD=0.26) compared to inactive controls 5. However, lithium's mechanism of enhancing serotonin neurotransmission 4, 2 provides biological plausibility for addressing this core depressive symptom.

Practical Dosing Protocol

Starting Dose

• Begin with 150 mg daily 1
• Alternative: 300 mg daily if tolerability allows 6

Target Serum Level

• 0.2-0.6 mEq/L for augmentation in depression 1
• This is substantially lower than the 0.6-1.2 mEq/L used for bipolar maintenance 6
• Lower levels (mean 0.33 mEq/L) have demonstrated efficacy with better tolerability 7

Titration Schedule

• Increase by 150-300 mg every 3-7 days based on tolerability
• Typical maintenance: 300-450 mg daily 7
• Maximum for augmentation rarely exceeds 600 mg daily

Timeline for Response

• Most responses occur within 1-2 weeks (76% of responders within 7 days) 7
• Continue for minimum 2 weeks before assessing response 2, 3
• If effective, maintain combination for at least 12 months to prevent relapse 2

Monitoring Parameters

Baseline (Before Starting)

• Serum creatinine and eGFR
• TSH and free T4
• Pregnancy test (if applicable)
• ECG if cardiovascular risk factors present
• Serum lithium level not needed at baseline

During Titration

• Serum lithium level after 1 week of stable dosing 7
• Draw 8-12 hours post-dose (trough level) 6
• Repeat weekly until therapeutic level achieved

Maintenance Monitoring

• Serum lithium: every 2 months once stable 6
• Creatinine/eGFR: every 3-6 months
• TSH: every 6-12 months
• More frequent monitoring if elderly or medically complex

Critical Safety Considerations

Absolute Contraindications 6

• Significant renal disease (eGFR <30-45 mL/min requires extreme caution)
• Severe cardiovascular disease
• Severe dehydration or sodium depletion
• Concurrent diuretic use (relative contraindication)

Common Pitfalls to Avoid

1. Don't use bipolar dosing targets: The 0.6-1.2 mEq/L range increases toxicity risk without added benefit for augmentation 1
2. Don't discontinue abruptly: Taper over weeks to months if stopping
3. Don't ignore drug interactions: NSAIDs, ACE inhibitors, and thiazide diuretics increase lithium levels
4. Don't forget hydration counseling: Dehydration rapidly increases toxicity risk

Signs of Toxicity (Even at Therapeutic Levels)

• Coarse tremor (vs. fine tremor at therapeutic levels)
• Confusion, ataxia, dysarthria
• Nausea, vomiting, diarrhea
• If suspected: hold lithium, check stat level, assess hydration

Comparative Context

Recent evidence suggests quetiapine augmentation may be more effective than lithium for overall depressive symptoms over 52 weeks 8, though lithium remains guideline-recommended as first-line 9, 10. The choice should consider:

• Lithium advantages: Anti-suicidal effects, decades of safety data, lower cost
• Quetiapine advantages: No monitoring requirements, possibly faster onset
• Patient factors: Tolerability concerns, monitoring feasibility, metabolic risk profile

Mechanism Relevant to Anhedonia

Lithium enhances serotonin neurotransmission through synergistic action with antidepressants on 5-HT pathways 4, 2. This mechanism is theoretically relevant to anhedonia, though direct evidence is limited. The low-dose approach (0.2-0.6 mEq/L) specifically targets increased serotonin turnover 7.

Duration of Treatment

If response achieved, continue lithium-antidepressant combination for minimum 12 months to prevent early relapse 2. Discontinuation before this increases relapse risk substantially. After 12 months, consider gradual taper with close monitoring if patient remains stable.